Northwest Biotherapeutics (NWBO) Other Accumulated Expenses (2014 - 2026)

Northwest Biotherapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $7.3 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses changed N/A year-over-year to $7.3 million in Q1 2026; TTM through Mar 2026 was $7.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $8.4 million, changed N/A from the prior year.
• Other Accumulated Expenses declined to $7.3 million in Q1 2026 per NWBO's latest filing, from $8.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $8.4 million in Q4 2025 and bottomed at $7.3 million in Q1 2026.